南京麦澜德医疗科技股份有限公司2025年第三季度报告

Group 1 - The company announced a delay in its fundraising projects, extending the completion date to December 31, 2026, for the headquarters production base, R&D center, and marketing service projects [11][21][22] - The delay is attributed to external factors such as environmental controls, weather conditions, and resource limitations, which have hindered construction progress [11][12] - The company emphasizes that the delay does not change the project content, implementation subjects, or investment scale, ensuring no harm to shareholder interests [21][22] Group 2 - The company reported a net profit of approximately 95.99 million yuan for the first three quarters of 2025, with a proposed cash dividend of 0.30 yuan per share [27][26] - The profit distribution plan is subject to approval at the upcoming shareholder meeting [28][29] - The total number of shares eligible for the dividend is 97,807,857 after excluding shares held in the repurchase account [27][26] Group 3 - The company appointed a new securities affairs representative, Mr. Shen Jiazhen, to assist the board secretary [32][33] - Mr. Shen has the necessary qualifications and experience to fulfill his duties [35] - The company will continue to ensure compliance with relevant regulations in its operations [33][35] Group 4 - The company is undergoing a change of registered address, moving from Jiangning District to a new location in the same district [36][37] - The change is part of the company's operational adjustments and requires shareholder approval [36][37] - The company will also revise its articles of association accordingly [36][37] Group 5 - The company has scheduled its third extraordinary general meeting for November 7, 2025, to discuss various proposals, including the profit distribution plan [39][40] - The meeting will utilize both on-site and online voting systems to facilitate shareholder participation [40][41] - Shareholders must register in advance to attend the meeting and participate in voting [49][50]